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Summary
In Alzheimer’s disease (AD) and Progressive
Supranuclear Palsy (PSP), the cross-linking of
phosphorylated tau into stable insoluble aggregates
may lead to formation of paired helical filaments (PHFs)
and neurofibrillary tangles (NFTs). NFT pathology is
accompanied by oxidative stress in AD and PSP.
Previous investigations have uncovered that
phosphorylated tau is cross-linked by transglutaminase
in the hindbrain of P301L tau transgenic mice. We
wanted to determine whether or not P301L mice would
exhibit oxidative pathology. To analyze this, we
performed immunoblots for the detection of modified
carbonyl groups on proteins in spinal cord tissue of
P301L tau transgenic, four-repeat wild-type (4RWT) tau,
and nontransgenic mice. Carbonyl levels were used as a
measure of oxidative stress. We found that P301L tau
transgenic mice exhibit more oxidative stress than
4RWT tau and nontransgenic animals. We are currently
orally administering cystamine, a transglutaminase
inhibitor and antioxidant, to P301L mice. Future
investigations will use this immunoblot technique to
evaluate the pleiotropic effects of cystamine on P301L
mice.
Introduction
Alzheimer’s disease (AD), Pick’s disease, Progressive
Supranuclear Palsy (PSP), and corticobasal degeneration
are characterized by neuropathological changes including
the aggregation of microtubule-associated protein tau (Lewis
et al., 2000). In the above tauopathies, abnormally
hyperphosphorylated tau polymerizes into straight and
paired helical filaments (PHF), which comprise neurofibrillary
tangles (NFT) (Halverson et al., 2005).The exact mechanism
that causes the formation of NFTs is unknown. The
accumulation of tau in neurodegenerative disorders (NDS) is
linked to a class of calcium dependent enzymes known as
transglutaminases (TGases) (Selkoe et al., 1982a). In vitro
studies demonstrate that tau is a substrate of
transglutaminase (Norlund et al., 1999), where tau is
modified at two glutamine and ten lysine residues to form a
cross-linked insoluble protein complex (Murthy et al., 1998).
In brain regions with extensive neurofibrillary pathology in
both AD and PSP, transglutaminase activity (Johnson et al.,
1997; Zemaitaitis et al., 2003) and transglutaminase
catalyzed-bonds found in PHFs and NFTs are significantly
elevated (Balin et al., 1999; Norlund et al., 1999; Zemaitaitis
et al., 2000; Singer et al., 2002). Despite recent findings, it
remains unclear whether PHF formation and tau cross-
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linking are involved in neurodegenerative pathogenesis or
whether they may have a neuroprotective function (Karpuj
et. al., 2004).
TGase may play a role in the pathogenesis of
CAG trinucleotide-repeat disorders, which are characterized
by proteins with expanded polyglutamine domains (Karpuj
et. al., 2002). Some examples of these proteins are tau and
huntingtin. TGase catalyzes the formation of _-glutamyl
isopeptide bonds between polyglutamine tracts and lysine
substrates (Folk et al., 1983; Green et al., 1993). The
resulting cross-linked protein complex is insoluble and
resistant to both proteolysis and denaturation (Selkoe et al.,
1982b). The understanding of the behavior of TGases in vivo
has led to investigations into the development of novel
therapies involving the use of TGase inhibitors such as
cystamine.
Recent studies have shown that cystamine is an in
vitro TGase inhibitor (Gentile et. al., 2004). Cystamine is
known to inhibit TGase through a disulfide exchange
reaction (Folk, 1980; Lorand et. al., 1984; Lorand, 1998). As
a primary amine, cystamine has a high affinity for TGase and
acts as a competitive inhibitor by blocking the active site of
the enzyme for glutamine residues (Lorand et. al., 1979). As
a result, cystamine may regulate the redox status of
neurons, playing a possible neuroprotective role.  Cystamine
has been found to be cytoprotective by increasing
glutathione levels in vitro. Glutathione is an antioxidant that
is a substrate for peroxides (Dedeoglu et. al., 2002). The
understanding of oxidative stress in NDS may provide a
comprehensive paradigm for the behavior of tau in
aggregation pathology.
In our previous investigation, we used P301L
transgenic mice which over-express a human isoform of tau
associated with frontal-temporal dementia (FTDP-17) (Lewis
et al., 2000). We also used four-repeat wild-type (4RWT) tau
transgenic and nontransgenic mice. The latter two model
organisms display no NFT pathology or symptoms (Lewis et
al., 2000). Our results have illustrated that tau protein from
the brain and spinal cord tissues of P301L tau transgenic
mice contain significantly more transglutaminase-catalyzed
cross-links than 4RWT tau and nontransgenic mice
(Halverson et al., 2005). Therefore, we hypothesized that
P301L mice would exhibit more oxidative stress in the spinal
cord than 4RWT tau and nontransgenic mice. This
hypothesis also follows the paradigm that neurodegeneration
is accompanied by aggregation pathology and oxidative
stress (Park et al., 2001). We also sought to determine
whether or not P301L mice were a good model of
tauopathies by determining the level of oxidative pathology
found in their spinal cords. Results from these experiments
will aid in understanding of current PSP investigations.
Our current research focuses on the investigation
of a potential drug therapy for PSP, using P301L mice
treated orally with cystamine. Other researchers have used
oral treatments of cystamine in R6/2 mice. A mutant form of
huntingtin protein is expressed in R6/2 mice and may be
cross-linked by transglutaminase to form intranuclear
aggregates. This event is followed by neuronal loss in the
striatum and cortex. Cystamine treatment was found to
increase survival by 20% in comparison to saline and
untreated littermates. Manifestations of aggregated
huntingtin protein were reduced by 70% in the striatum and
by 50% in the cortex (Dedeoglu et al., 2002). These findings
suggest a possible usefulness of cystamine in P301L mice.
We  investigated  whether  or  not cystamine would   prolong
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Figure 1A. OxyBlot Control Experiment
Gel displays control experiments run to determine efficacy of reagents. DNPH indicates that a derivatization reaction was performed on the tissues
specified. Oxidized proteins were detected in relatively equal concentrations within AD cortex, nontransgenic (NTG), and 4RWT spinal cord tissues.
P301L tau transgenic tissue showed very little oxidation in comparison to other derivatized samples.The immunoblots were reprobed with an antibody
against actin to demonstrate relatively equal protein loading among lanes.  Molecular mass in kilodaltons (kDa) is indicated on the left. The film was
exposed for 3 minutes.
Figure 1B. OxyBlot DNPH Experiment
AD tissue loaded into the gel was not derivatized. Nontransgenic (NTG), 4RWT, and P301L spinal cord tissues were derivatized. Nontransgenic and
4RWT tissues exhibited uniform oxidation. One P301L sample appeared to display significantly (statistics were not performed) greater intensity than
any other sample. The immunoblots were reprobed with an antibody against actin to demonstrate relatively equal protein loading among lanes.
Molecular mass in kilodaltons (kDa) is indicated on the right. The film was exposed for 3 minutes.
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Table 1. Behavioral Scoring Rubric
Scores used to asses criteria for sacrificing mice. Behavioral tests adapted from Karl and colleagues (2003).
Righting ReflexS1
0 1 2
0 0 2 4
1 10 12 14Tail Hang
2 14 16 22
Tail Hang (Scoring 0-2)
0- Mouse when lifted by tail displays standard escape response, legs in “V” position
1- Mouse does not exhibit full escape response (poor escape), inward trend with legs
2- Mouse maintains legs in a scissored, clasped (clenched), or dystonic position
Righting Reflex (Scoring 0-2)
0- Mouse can right when placed supine
1- Mouse righting slowed
2- Mouse unable to right
Wire Hang TimeS2
0 (120s) 1 (60s-120s) 2 (5s-60s) 3 (0s-5s)
0 0 1 3 5
1 1 2 4 6
2 3 4 5 7
Wire Hang
Behavior
3 5 6 7 8
Wire Hang Behavior (Scoring 0-3)
0- Can complete test with at least three paws and tail within two minutes, climber
1- Can hold on to rope without falling until end, does not complete
2- Falls before two minutes without completion
3- Unable to perform test, slips off the wire
Wire Hang Time (Scoring 0-3)
0- Hangs on for full 120 seconds
1- Hangs on between 60 seconds and 120 seconds
2- Hangs on between 5 seconds and 60 seconds
3- Hangs on for less than 5 seconds
Total Score = S1 + S2
Normal Mild/Early Moderate/Mid Severe/End
0-12 13-20 21-23 24-30
survival and decrease motor impairments in P301L mice
when compared to untreated P301L mice.
Results
Oxidative Pathology Found in P301L Transgenic Mice
We wanted to determine if oxidative stress is elevated in the
spinal cords of symptomatic P301L tau transgenic mice. To
measure oxidative stress, we utilized the OxyBlot protein
oxidation detection kit from Chemicon. A control blot was run
to determine efficacy of reagents in the OxyBlot kit (Figure
1A). Alzheimer’s disease parietal cortex tissue was used as
a positive control where oxidative stress pathology is
expected. There seems to be no significant difference in
band intensity among the three positive control lanes (3, 5,
and 7). Tissue used in lane 9 was obtained from a
symptomatic animal of unknown age. This may explain the
lack of intensity found in this lane. A high range rainbow
molecular weight marker (BioRad) with 2-mercaptoethanol
(reducing agent) served as an internal control for
electrophoresis.
Oxidized proteins were significantly increased in
one symptomatic transgenic animal (lane 12, 13 months of
age, Figure 1B) compared to age-matched non-transgenic
controls. Symptomatic P301L transgenic animal tissue used
in lanes 10 (4.3 months), 11 (4.3 months), and 13 (unknown
age) were not age-matched. These symptomatic mice did
not show significant differences in oxidized proteins when
compared to asymptomatic animals.
Treated Mice Consume More Water
Current research in our laboratory involves the use of
cystamine as a therapeutic agent to treat symptomatic
P301L tau transgenic mice. Cystamine dihydrochloride was
orally administered (157mg/kg/day) via water bottles. Control
group received regular tap water. Consumption was checked
everyday in the mid-morning. Cystamine treated mice
consumed about 14.9%, on average, more than non-treated
mice over the past year (July 2004 to July 2005) (Figure 2).
Cystamine does not Ameliorate Weight Loss
Mice were weighed twice a week during behavioral testing to
normalize   the   concentration   of   cystamine
administered(157mg/kg/day). A hallmark of disease
progression in P301L mice is weight loss. Dedeoglu and
colleagues (2002) reported improved body weight by 12.6%
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Figure 2. Average Monthly Consumption of P301L Tau Transgenic Mice
An experimental group of P301L tau transgenic mice were supplemented with cystamine (157mg/kg/day) at 2 months of age. A control group was
treated with water. Consumption was recorded daily. Graph displays average consumption for every month. Preliminary data shows that cystamine
supplemented animals consume more than non-supplemented animals.
For R6/2 mice supplemented with cystamine. Based on this
study we expected cystamine to ameliorate weight loss in
P301L transgenic animals. Preliminary data shows no
significant difference in weight among treated and non-
treated groups (Figure 3).
Cystamine Treated Mice do not Live Longer
We hypothesized that cystamine treatment would extend the
survival of P301L mice based on similar work done by
Dedeoglu and colleagues (2002). Our preliminary data
suggest that cystamine does not extend survival in P301L
transgenic mice. Data does, however, show that after onset
of first symptoms cystamine treated mice develop moderate
symptoms (Table 1) about 33 days after non-treated mice.
Figure 4 in the appendix shows the behavioral progress of
treated and non-treated P301L mice. Results of preliminary
data on motor performance suggest no apparent differences
in phenotypic onset of symptoms between treated and non-
treated mice.
Discussion
The central goal of taupathy research is to understand how
tau accumulates and determine whether or not it leads to
neurotoxicity in Alzheimer’s disease, Progressive
Supranuclear Palsy, and Frontal Temporal Dementia. This
research may than provide scientists with therapeutic targets
to prevent the processes that lead to neuronal death. Yet, in
order to understand the mechanisms underlying these
diseases, a holistic picture including oxidative stress must be
rendered.
P301L Transgenic Mice Exhibit Oxidative Pathology
OxyBlot experiments performed with P301L spinal cord
tissue gave insight into the progression of oxidative
pathology in P301L tau transgenic mice. Animals used for
lanes 10 (5.5 months) and 11(5.5 months) (Figure 1B)
displayed onset of disease related behavioral phenotype, yet
did not show any significant differences in oxidative
pathology when compared to asymptomatic mice. We can
speculate that levels of oxidative stress in P301L spinal cord
tissue cannot be used as an early marker for disease
progression. Tissue of a much older specimen (13 months,
lane 12, Figure 1B) showed significantly more oxidation than
any other sample. This result shows the potential of
oxidative damage that can be done in this animal model.
These experiments advocate the use of P301L mice
supplemented with cystamine in OxyBlot assays. The animal
model manifests extreme oxidative pathology in end-stage
(Table 1) behavioral phenotypes which provide cystamine an
opportunity to demonstrate the extent of its suggested anti-
oxidant effects.
Future OxyBlot Assays with Cystamine Treated Mice
Oxyblot experiments were performed for two reasons. First,
we wanted to determine if there are higher levels of
oxidatively modified proteins in the spinal cord and hindbrain
of P301L tau transgenic mice when compared to
asymptomatic 4RWT tau and nontransgenic mice. Second,
we wanted to optimize the efficacy of the OxyBlot protocol
for  testing   cystamine  treated  and  non-treated  P301L  tau
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Figure 3. Average Monthly Weight Gain for P301L Tau Transgenic Mice
Weights were recorded twice every week during behavioral testing. Graph shows that there is no difference in weight gain for treated and non-treated
animals.
Figure 4. Behavior and Symptom Summary
The graph shows a record of the number of P301L mice in a particular symptom category as of July 2005. Tail hang, righting, and wire hang behavioral
tests were performed twice a week beginning in July 2004. The criteria for each symptom group (normal, mild, moderate, severe, dead) was
determined by a scoring rubric (Table 1). We began with a total of 32 mice. Four water treated mice died at an age of 5.5 months from hypothermia
due to a leaky water bottle.
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transgenic mice in the future. We expect to see decreased
levels of oxidative stress in cystamine treated animals
because of the drugs recognized anti-oxidant effects. The
drug’s ability to inhibit transglutaminase may decrease NFT
formation which may directly impact the redox status of the
cell.
Cystamine may have an Effect on Energy Metabolism
Knowledge of cystamine’s antioxidant effects may give
insight into abnormalities in glucose metabolism found in
PSP (Park et al., 2001). Current research has shown P301L
mice supplemented with cystamine consume more than non-
treated animals (Figure 2). This begs the question that
cystamine’s antioxidant effects may have an effect on
energy metabolism in symptomatic P301L tau transgenic
mice. Supplemented animals seem to be more active than
non-treated mice, especially from October 2004 to March
2005. However, behavioral and weight assessments show
no significant differences (Figure 3) in treated mice. In a
different tauopathy, Dedeoglu and colleagues (2002) found
that cystamine significantly improved motor performance and
delayed pathology in a murine model of Huntington’s
disease. Our evaluations do not support their findings.
Mitochondrial Impairment Increases Oxidative Stress in PSP
It has been shown that oxidative stress is present in PSP
brains with decreased activity of a mitochondrial enzyme,
alpha-ketoglutarate dehydrogenase (KGDHC) (Park et al.,
2001). KGDHC is a rate-limiting enzyme in the Krebs cycle.
Irregularities in energy metabolism by mitochondrial
dysfunction and oxidative stress are associated with
neuronal loss in AD and PSP. This has been confirmed by
studies of glucose metabolism in PSP patients using
positron emission tomography (PET). PSP patients are seen
to have reduced glucose utilization in the frontal cortex and
basal ganglia structures (Chirichigno et al., 2002). The cause
and consequences of such mitochondrial dysfunction remain
unknown. However, Albers and colleagues (2001) have
proposed a mechanism involving oxidative pathology found
in PSP.
ROS Increase Cytoplasmic Calcium Levels which Activate
TGase
A compensatory cellular response to increased free radical
production is upregulation of antioxidant defense systems,
such as superoxide dismutase (SOD) and gluthathione
(Albers et al., 2001). Yet, these defense mechanisms do not
have the capacity to scavenge ROS found in PSP pathology.
Oxidative pathology has also been shown to increase
intracellular calcium levels in two ways. First, ROS
decreases activity of plasma membrane calcium ATPase
activity (Powers et al., 2005). The inactivity of this enzyme
hinders the movement of calcium in and out of the cell.
Second, the endoplasmic reticulum serves as an intracellular
calcium store. In the presence of ROS, these calcium stores
are lysed open by lipid peroxidation (Mattson et al., 1997).
Calsequestrin, which binds calcium in the cytoplasm, is also
upregulated in the presence of ROS (Hunter et al., 2001).
Oxidative stress is also associated with abnormalities in
energy metabolism, as mentioned above. Hypoglycemia has
been shown to increase intracellular calcium levels (Cheng
et al., 1992). All of these conditions make a suitable
environment for the activity of transglutaminase. The
concentration of calcium required for activation of TGase is
higher than the physiological range associated with most
intracellular processes (Karpuj et. al., 2004). High
intracellular calcium levels also upregulate caspases, which
are a group of cysteine proteases. Tau is a substrate for the
apoptotic protease caspase-3. After cleavage, tau is turned
into an effector of apoptosis, generating a self-propagating,
positive-feedback loop (Fasulo et al., 2005). These caspase
cleaved fragments of tau may serve as a better substrate for
TGase (Karpuj et al., 2004). This evaluation gives us clues
into how cystamine will perform in P301L mice.
P301L Transgenic Mice are not Effective Tauopathy Models
Cystamine may provide effective therapies to the
aforementioned conditions in PSP neuropathology.
Cystamine has been mentioned to increase antioxidant
levels within the cell and inhibit transglutaminase. Cystamine
also serves as a caspase-3 inhibitor, which would possibly
decrease the probability of transglutaminase catalyzed
cross-linking of tau (Ientile et al., 2003). Future directions
may involve the creation of better transgenic mice to model
PSP. P301L tau transgenic mice used are an extreme model
of PSP, which may set the bar higher for any successful
therapeutic approach with cystamine.E
Experimental Procedures
Animals
Female P301L tau transgenic mice were obtained from TaconicTM
(Germantown, NY) at two months of age and were assessed for
motor disturbances using behavioral tests as an indication for disease
progression twice a week. Body weights were recorded during this
time. A behavioral scoring rubric was constructed to chart this
progress (Table 1). Tail hang, righting reflex, and wire hang tests
were performed according to Karl and colleagues (2002). Once mice
arrived to an end-stage behavioral phenotype consisting of a score
between 24 and 30 (Table 1), they were sacrificed. Mice were also
observed for poor grooming and gait, deficient body posture, reduced
weight loss, and development of eye irritations. These criteria were
evaluated before euthanasia by cervical dislocation. 4RWT tau
and nontransgenic mice were also obtained from Taconic. The age of
the animals used in this experiment ranged from 10 to 16 months,
where 4RWT tau (n = 4) and nontransgenic mice (n = 4) were age
matched to P301L tau transgenic mice (n = 1). Due to lack of aged
mice tissue, spinal cord OxyBlot experiments were performed with
two P301L tau transgenic mice that were sacrificed at 4.3 months.
Drug Treatment
Cystamine dihydrochloride (MW 225.2), purchased from ICN
Biomedicals Inc. (Irvine, CA), was orally administered (157mg/kg/day)
to P301L tau transgenic mice via water bottles. Control group was
given regular tap water. Consumption was recorded daily in the mid-
morning.
Human Tissue
Human AD cortex tissue from pathologically confirmed cases was
obtained from the Loyola University Brain Bank (Maywood, IL).
Tissue Harvest
Brain and spinal cord tissue were extracted from sacrificed mice and
then cooled rapidly to minus 80°C. This procedure used a flash
freezing technique. After the brain was extracted, it was rinsed in 0.9
% saline solution and was cut into two hemispheres. A prepared
methanol bath was cooled with dry ice. A 10 ml beaker was filled with
isopentane and placed in the ethanol bath to cool. Each hemisphere
was placed in the isopentane for approximately 5 minutes or until air
bubbles finished emerging from the tissue and changed to a whitish
hue. The spinal cord was extracted and cooled by placing it in
parafilm on dry ice. Spinal cord could not be flash frozen because of
its delicate make-up. The tissues were massed before storage at
minus 80°C.
Tissue Preparation
Spinal cord tissue from P301L tau, 4RWT tau, and nontransgenic
mice was processed using Dounce homogenizing tubes with glass
pestles in three volumes of TBS (10mM Tris-HCl, pH 7.5, 0.14 M
NaCl), 1 mM EDTA, and 1:1000 protease inhibitor cocktail from
Sigma (St. Louis, MO) (Halverson et al., 2005).
Determining Protein Concentration
BCA Protein Assay Kit from Pierce (Rockford, IL) with a detergent-
compatible formulation based on bicinchoninic acid (BCA) was used
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for the colorimetric detection and quantification of total protein in
homogenate. Unknown protein concentrations were determined by
comparison to serial dilutions (0, 1, 2, 4, 7, 15, 20 µg/µl) of known
standard protein concentrations from bovine serum albumin (BSA).
Each prepared standard and sample were loaded into a 96 microwell
plate in triplicates. The plate was then gently shaken and allowed to
incubate at 37°C with a cover plate for 30 minutes. Samples were
read on a BioRad Microplate Spectrophotometer (Model 680) at 540
nM. Final unknown protein concentrations were determined by
interpolating values made from a curve of standard values from BSA.
Derivatization of Carbonyl Groups
OxyBlot Protein Oxidation Detection Kit was obtained from Chemicon
International (Temecula, CA) and was used to perform immunoblot
detection of modified proteins by carbonyl groups. Samples were
prepared with a final protein concentration of 20 µg. Carbonyl groups
in samples were derivatized to 2,4-dinitrophenylhydrazone (DNP-
hydrazone) by reaction with 2,4-dinitrophenylhydrazine (DNPH).
Samples were stored at 4°C until ready to load on polyacrylamide
gel.
Western Blotting
The derivatized samples were separated by a polyacrylamide gel
(12%) electrophoresis at 200 volts and transferred onto a
nitrocellulose membrane at 100 volts for 2 hours at 16°C. The
membranes were then blocked with 1% BSA-PBS-Tween 20 for 1
hour at room temperature. A rabbit anti-DNP (1:150 diluted in 1%
BSA-PBS-Tween 20) primary antibody was used to probe the
membranes overnight at 4°C. Membranes were rinsed twice with 1X
PBS-Tween 20 and then washed for 15 minutes, followed by 2
washes for 5 minutes. A goat anti-rabbit IgG (1:300 diluted in 1%
BSA-PBS-Tween 20), Horse radish peroxidase (HRP) conjugated,
secondary antibody was used to probe the membranes for 1 hour at
room temperature. The membranes were rinsed and washed as they
were after probing with the primary antibody. Chemiluminescent
reagents (1:1 luminal and enhancer) from Amersham Biosciences
(Buckinghamshire, England) were used to treat the membranes for
development by short exposure to blue-light sensitive films from
Denville Scientific Inc. (Metuchen, NJ). Antibodies for
immunodetection were supplied by the OxyBlot kit.
Actin Probing
Membranes were washed twice with 1% BSA-PBS- Tween 20 for 5
minutes and then stripped with 1M NaOH for 10 minutes at room
temperature and washed again. The membranes were then
reblocked with 5% BSA-PBS-Tween 20 for 1 hour at room
temperature and subsequently probed with monoclonal actin (clone
4), which is a mouse IgG (gamma 1 heavy/kappa light chain)
antibody (1:15,000 diluted in 0.1% BSA-PBS, pH 7.6, with 0.1%
sodium azide) from MP Biomedicals, Inc. (Aurora, OH) for 1 hour at
room temperature. Washing was then performed three times for 5
minutes. A rabbit anti-mouse IgG, HRP-conjugated, secondary
antibody (1:10,000 diluted in 1% BSA-PBS-Tween 20) from Jackson
Immuno Research Laboratories, Inc. (West Grove, PA) was used for
1 hour. Membranes were developed as done in the OxyBlot protocol.
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